SIRPα blockade therapy potentiates immunotherapy by inhibiting PD-L1+ myeloid cells in hepatocellular carcinoma



Summary

SIRPα blockade enhances immunotherapy effectiveness in hepatocellular carcinoma (HCC) by targeting a specific subset of myeloid cells. These myeloid cells, which express PD-L1, dampen the immune response against cancer cells. Blocking SIRPα disrupts the “don’t eat me” signal normally used by cancer to evade immune cells, particularly macrophages. By inhibiting these PD-L1+ myeloid cells, SIRPα blockade reduces immunosuppression, allowing for increased T-cell activation and improved anti-tumor immunity. Consequently, this approach potentiates the effects of other immunotherapies, offering a promising strategy for treating HCC.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!